All AbMole products are for research use only, cannot be used for human consumption.
For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.
Meclofenamic acid (Meclofenamate) sodium hydrate is a non-steroidal anti-inflammatory agent. Meclofenamic acid sodium hydrate is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid sodium hydrate competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid sodium hydrate is a non-selective gap-junction blocker. Meclofenamic acid sodium hydrate inhibits hKv2.1 and hKv1.1, with IC50 values of 56.0 and 155.9 μM, respectively.
| Molecular Weight | 336.15 |
| Formula | C14H12Cl2NNaO3 |
| CAS Number | 67254-91-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Related FTO Products |
|---|
| Entacapone
Entacapone is an inhibitor of FTO demethylation with IC50 of 3.5 μM, Entacapone also inhibits catechol-O-methyltransferase (COMT) with IC50 of 151 nM. |
| Rhein
Rhein, also known as cassic acid, is a substance in the anthraquinone group obtained from rhubarb. |
| FB23
FB23 is a potent and selective FTO demethylase inhibitor with an IC50 of 60 nM. FB23 binds to FTO and selectively inhibits FTO's mRNA N6-methyladenosine (m6A) demethylase activity. |
| FB23-2
FB23-2 is a potent and selective FTO inhibitor with an IC50 of 2.6 μM, directly binds to FTO and selectively inhibit FTO's m6A demethylase activity. |
| Dac51
Dac51 is an effective FTO inhibitor with an IC50 of 0.4 μM against FTO demethylation. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
